# Greater Los Angeles Clinical Center of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer

> **NIH NIH U01** · CEDARS-SINAI MEDICAL CENTER · 2020 · $523,936

## Abstract

This is an application for renewal of Clinical Center designation of the Consortium for the Study of Chronic
Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). The Greater Los Angeles Clinical Center has provided
considerable leadership in the organization and progress of the CPDPC. Dr. Pandol serves as co-chair of the
Steering Committee and Dr. Goodarzi co-chairs the Type 3c Working Group. We have excelled in recruitment
and retention of participants in the cohort studies implemented through the CPDPC designed to elucidate the
natural history and develop means of diagnosis, treatment and clinical management of chronic pancreatitis (CP)
and its complications in children and adults, and to determine the pathogenic interrelationships of diabetes and
pancreatic cancer and develop the means of early diagnosis and management of pancreatic cancer. In addition,
we have been performing a number ancillary and associated studies to support the overall goals of CPDPC,
including: 1. Epidemiologic studies defining risk factors for pancreatic cancer and the natural history of CP; 2.
Determining that genetic susceptibility for type 2 diabetes is a strong risk factor for diabetes associated with CP;
3. Developing liquid biopsy assays for aiding in the diagnosis of pancreatic cancer and CP; 4. Investigating
mechanisms of pancreatitis and pancreatic cancer for rational pharmaceutical treatments; and 5. Conducting
pilot clinical trials for treatment of recurrent acute and chronic pancreatitis. For the next phase of the CPDPC we
are committed to the following Specific Aims:
1. Continue recruitment and retention of subjects in CPDPC cohort studies (PROCEED, INSPPIRE 2, NOD,
 DETECT) in existing and additional study sites, as well as increase diversity in the study population.
2. Continue currently supported ancillary studies to further develop risk factor models combined with liquid
 biopsy assays for early diagnosis of chronic pancreatitis and pancreatic cancer, and advance mechanism-
 based treatments and clinical trials for recurrent acute and chronic pancreatitis and pancreatic cancer.
3. Build models that combine clinical features with genetic susceptibility to allow the prediction of future
 development of diabetes in patients with chronic pancreatitis.
4. Determine the role of pancreatic enzyme replacement in regulating glucose homeostasis in patients with
 chronic pancreatitis and diabetes, with or without pancreatic exocrine insufficiency.
5. Use existing and annotated pre-diagnostic CT scans to develop artificial intelligence-based techniques for
 highly sensitive and specific methods for CT-based early pancreatic cancer detection.
Our Center involves Cedars-Sinai Medical Center, UCLA Medical Center, the VA Greater Los Angeles
Healthcare System and the University of Southern California/Los Angeles Public Health System with an
organizational structure designed to expand recruitment into cohort studies of CPDPC with increased diversity
and to facilitate o...

## Key facts

- **NIH application ID:** 10074162
- **Project number:** 2U01DK108314-06
- **Recipient organization:** CEDARS-SINAI MEDICAL CENTER
- **Principal Investigator:** Mark Goodarzi
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $523,936
- **Award type:** 2
- **Project period:** 2015-09-28 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10074162

## Citation

> US National Institutes of Health, RePORTER application 10074162, Greater Los Angeles Clinical Center of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (2U01DK108314-06). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10074162. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*